Designer Phages Market Gains Momentum as Precision Therapeutics and Advanced Biotechnologies Drive Innovation
Growing investment in precision medicine, rising antimicrobial resistance, expanding applications in agriculture, and rapid advancements in phage engineering are accelerating the growth of the designer phages market.
The global Designer Phages Market size was valued at USD 1.57 billion in 2024, with an estimation of USD 1.70 billion in 2025 and is predicted to reach USD 2.49 billion by 2030 with a CAGR of 8.0% from 2025-2030.
Download FREE Sample
Beyond healthcare, designer phages are gaining traction in agriculture and food production as sustainable biological solutions for controlling plant diseases, bacterial contamination, and pest infestations. Their ability to reduce reliance on chemical pesticides and antibiotics aligns with global sustainability initiatives while supporting safer agricultural practices. Growing collaboration between research organizations, pharmaceutical companies, and academic institutions is further expanding commercial opportunities across multiple sectors.
Key Players
• BiomX Ltd. • Micreos • Phaxiam • Locus Biosciences, Inc. • Proteon Pharmaceuticals • Cytophage Technologies Ltd. • Armata Pharmaceuticals, Inc. • SNIPR Biome ApS • PrecisionPhage • MEDEA Biopharma • Eligo Bioscience • Intralytix, Inc. • PhagePro, PBC • Eliava BioPreparations Ltd.
Competitive Landscape
The market is moderately competitive, with biotechnology innovators, pharmaceutical companies, and research organizations focusing on developing next generation phage based therapeutics and biological solutions. Companies are investing in genetic engineering, synthetic biology, and precision phage platforms to improve treatment efficacy while expanding applications across healthcare, agriculture, food safety, and veterinary medicine.
Conclusion
The Designer Phages Market is poised for sustained growth as precision medicine, synthetic biology, and antimicrobial resistance solutions become increasingly important worldwide. Continued advancements in phage engineering, expanding applications across healthcare and agriculture, and rising investment in innovative biologics are expected to drive long term market expansion and establish designer phages as a critical component of future targeted therapies.